# Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Canonical URL: https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-additional-positive-phase-3-results-for-lonvoguran-ziclumeran-lonvo-z-in-patients-with-hereditary-angioedema
Ticker: NTLA
Company: Intellia
Source: Intellia
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.intelliatx.com
## Summary

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) --

## Article Body
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) --
## Recent Company News
- 2026-06-25 13:46 EST — [Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-additional-positive-phase-3-results-for-lonvoguran-ziclumeran-lonvo-z-in-patients-with-hereditary-angioedema) — Source: Intellia
- 2026-06-25 13:46 EST — [Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-report-additional-phase-3-haelo-data-for-lonvoguran-ziclumeran-lonvo-z-in-late-breaking-oral-presentation-at-eaaci-2026) — Source: Intellia
- 2026-06-25 13:46 EST — [Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates) — Source: Intellia
- 2026-06-25 13:46 EST — [Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-presents-longer-term-clinical-data-for-lonvoguran-ziclumeran-lonvo-z-hereditary-angioedema-hae-patient-focused-research-at-aaaai-2026) — Source: Intellia
- 2026-06-25 13:46 EST — [Intellia Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Intellia
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)